U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07232030) titled 'Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure' on Nov. 14.
Brief Summary: The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF < 50% and NT-proBNP < 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (C...